Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Full Year Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221130:nRSd0014Ia&default-theme=true

RNS Number : 0014I  Benchmark Holdings PLC  30 November 2022

30 November 2022

 

Benchmark Holdings plc

 

("Benchmark", the "Company" or the "Group")

 

Full Year Results for the Financial Year ended 30 September 2022

 

A year of sustained growth and strategic delivery

 

Benchmark, the aquaculture biotechnology company, announces its full year
audited results for the year ended 30 September 2022 (the "period").

 

Financial highlights - strong FY2022 results delivered ahead of original
market expectations

 

·   Revenue increase of 27% (+21% CER)

o Advanced Nutrition - excellent performance as the Company continued to
capitalise on renewed commercial focus and recovery in the shrimp markets post
pandemic; revenues increased by 14% (+7% CER)

o Genetics - strong performance benefitting from high demand for the
Company's salmon eggs delivered from Benchmark's new incubation centre in
Iceland; revenue growth +24% (+21% CER)

o Health - first full year of sales from new sea lice solution Ectosan® Vet
and CleanTreat® resulting in revenue growth of 157% (+157% CER)

·    Adjusted EBITDA +60% (+54% CER) driven by growth in the three
business areas and continued financial discipline

·  Adjusted EBITDA margin of 20% (FY21: 16%). Adjusted EBITDA margin
excluding fair value uplift from biological assets increased to 19% (FY21:
13%)

·   Loss for the period increased to £30.5m as a result of increased
depreciation associated with CleanTreat® units and higher net finance
expenses

·   Disciplined investment in growth areas with tangible capex totalling
£10.8m

·   Refinancing of NOK 850m bond and post period end refinancing of USD
$15m RCF

·   Cash and cash equivalents of £36.4m and available liquidity of
£45.8m

·   At 28 November, cash and cash equivalents of £35m and available
liquidity of £51m

 

 £m                                                                  FY 2022  FY 2021  % AER   % CER**
 Revenue                                                             158.3    125.1    27%     21%
 Adjusted
 Adjusted EBITDA(1)                                                  31.2     19.4     60%     54%
 Adjusted EBITDA excluding fair value uplift from biological assets  29.6     16.1     83%     76%
 Adjusted operating profit                                           9.1      10.8     (15%)   (23%)
 Statutory
 Operating loss                                                      (7.9)    (5.4)    (46%)   (61%)
 Loss before tax                                                     (23.2)   (9.2)    (152%)  (167%)
 Loss for the period                                                 (30.5)   (11.6)   (163%)  (168%)
 Basic loss per share (p)                                            (4.60)   (1.93)   (138%)
 Net debt(3)                                                         (73.7)   (80.9)   9%
 Net debt excluding lease liabilities                                (47.5)   (56.9)   17%

 

** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

 

 

 Business Area Performance - £m                                  FY 2022  FY 2021  % AER  % CER**
 Revenue
 Genetics                                                        58.0     46.8     24%    21%
 Advanced Nutrition                                              80.3     70.5     14%    7%
 Animal Health                                                   20.1     7.8      157%   157%
 Adjusted EBITDA(1)
 Genetics                                                        16.0     11.5     39%    39%
 -       Net of fair value movements in biological assets        14.4     8.2      75%    76%
 Advanced Nutrition                                              19.0     13.8     38%    29%
 Animal Health                                                   0.1      (2.7)    104%   102%

 

** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.

 

Operational highlights

 

Advanced Nutrition - excellent performance

·  Excellent performance driven by commercial focus, continued innovation
and cost discipline, supported by positive market conditions

·  New products and product upgrades brought to market including Artemia
separation tool 'Sep-Art Automag' which delivers sustainability benefits

·   Closure of trial facilities in Thailand as part of strategy to
optimise operations

 

Genetics - continued growth

·   Continued growth in core salmon egg business with record sales in
FY2022

·  New incubation centre in Iceland delivering increased quality and
capacity which was instrumental in satisfying peak demand in the year

·   Commercialisation of SPR shrimp progressing, leveraging Advanced
Nutrition's market position in shrimp

 

Health - further commercialisation progress

·   Roll-out of Ectosan® Vet and CleanTreat® progressing with increasing
customer adoption. Solution delivered consistent efficacy above 99%, with
enhanced animal welfare and protection of the environment

·    Marketing Authorisation for Ectosan® Vet and CleanTreat® in Norway
extended to one reuse of water

·    Marketing Authorisation obtained in the Faroe Islands

·    Ectosan® Vet patent grant approved giving 20 year protection

 

Group - ESG commitment, continued integration and delivery against strategic
priorities

·   ESG - on track to achieve our Net Zero targets with implementation of
carbon reduction plan; issue of first Green bond validates strong ESG
credentials

·   Continued Group integration by combining the commercial efforts across
our salmon products, making the business more customer-centric and increasing
efficiency

·   Excellent employee engagement results aligned to the Group's goal of
making Benchmark "A Great Place to Work"

·    Looking forward we remain focused on our four strategic pillars:

o Maintain and grow our leadership position in established markets

o Expand our business through the launch of new products and entry into new
markets

o Continue to embed the new One Benchmark culture and to integrate the Group
to realise synergies

o Pursue add-on acquisitions within core areas, adhering to strict criteria
and making optimal use of our capital structure

 

Current trading and outlook - good momentum and tracking in-line with
management expectations

·  Good start to the year and positive momentum in the business

·  The diversified nature of the business and management's proactive
commercial approach creates resilience and mitigates the potential impact from
ongoing cost inflation and macroeconomic pressures

· Management expects that the recently announced change in tax regime for
aquaculture producers in Norway will have a marginal direct effect on the
Group's business

· Well progressed towards dual listing on Euronext Growth Oslo as announced
this morning; intention to uplist to the Oslo Børs in H1 calendar year 2023

· Longer term, management believe the Group is uniquely positioned in an
industry that is structurally growing driven by megatrends

 

Trond Williksen, CEO, commented:

"In FY2022 Benchmark delivered another year of growth and strategic progress,
underpinned by four quarters of consistently improved financial results. This
demonstrates the success of our restructuring and culture change, the quality
and potential of our business and the talent and commitment of our people, as
well as the underlying strength of our markets.

"Our strategic and commercial focus have contributed to strong results. Going
into the new financial year, there is good momentum in line with our
expectations and positive dynamics in our industry creating significant
opportunities to deliver value for all our stakeholders."

 

Details of analyst / investor call today

There will be a call at 9.00am UK time today for analysts and investors. To
attend the call, please register via Investor Meet Company:
https://www.investormeetcompany.com/benchmark-holdings-plc-analyst-meeting-q4-results/register-investor
(https://www.investormeetcompany.com/benchmark-holdings-plc-analyst-meeting-q4-results/register-investor)
.

 

You can address registration questions to MHP Communications on +44 (0)20 3128
8004, or by email on benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com) .

 

Enquiries

 

 Benchmark Holdings plc                           Tel:  0114 240 9939
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Numis (Broker and NOMAD)                         Tel:  020 7260 1000
 James Black, Freddie Barnfield, Duncan Monteith

 MHP                                              Tel:  020 3128 8004
 Katie Hunt, Reg Hoare, Veronica Farah            benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)

 

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their
sustainability and profitability. We bring together biology and technology, to
develop innovative products which improve yield, quality and animal health and
welfare for our customers. We do this by improving the genetic make-up, health
and nutrition of their stock - from broodstock and hatchery through to nursery
and grow out. Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics and sea lice
treatments. Find out more at www.benchmarkplc.com
(http://www.benchmarkplc.com)

 

Chairman's Statement

 

A year of delivery

I am proud to report a second year of strong performance for Benchmark,
continuing a path that started in 2019 with a substantial reorganisation of
the business and the appointment of a new management team.

 

In 2022 our focus was on delivering profitable growth in each of our
established core areas, on fully commercialising our recently launched
products, and on maintaining disciplined cash management and investment.
Together, this translated into a very strong performance with significant top
line growth and improved underlying profitability. We remain committed to
continuing on this path of consistent delivery to reach sustainable
profitability and cash generation, and ultimately attractive shareholder
returns.

 

Macroeconomic and geopolitical conditions in the year materially affected
markets around the world and impacted the performance of our shares. Smaller
growth companies were particularly affected by fund outflows and a change in
investor sentiment. This is particularly disappointing given the significant
progress that the Company made during the year. However, I am confident that
we are building fundamental value for our shareholders, which will crystallise
in the coming years.

 

Performance

The Group delivered excellent growth in the year with a 27% increase in
revenue and an 83% increase in Adjusted EBITDA excluding fair value movements
from biological assets. Importantly, each of our three business areas
delivered higher revenues and Adjusted EBITDA, with growth in established
areas and progress in the commercialisation of new solutions, including
Ectosan® Vet and CleanTreat® and SPR shrimp genetics. We now have a solid,
diversified, well-balanced Group across geographies and species which provides
multiple opportunities for growth as well as resilience to volatility in
specific markets.

 

Adjusted EBITDA is the key profitability measure we use to track underlying
performance. In FY22 the Group delivered Adjusted EBITDA of £31.2m (FY21:
£19.4m) and an Adjusted EBITDA margin of 20% (FY21: 16%) as a result of top
line growth, increased asset utilisation and good cost control.

 

There was an increase in depreciation related to our CleanTreat® operations
and higher net finance costs reflecting foreign exchange volatility as well as
costs associated with the refinancing of our pre-existing NOK bond. This led
to a net loss for the year of £30.5m (FY21: £11.6m loss).

 

Financing

An area of focus for the Board in FY22 was to maintain a solid financial
position to support the Company's trading momentum and growth strategy. To
this end, in November 2021 the Company raised £20.7m through a placing of
shares with existing and new shareholders which provided additional headroom.
Later in the year, in September 2022, in challenging macroeconomic and market
conditions, the Company successfully refinanced its NOK 850 million bond which
was due to mature in June 2023. The refinancing was achieved through the issue
of a NOK 750 million unsecured green bond maturing in 2025 which validates our
strong ESG credentials, and places us in a solid financial position,
particularly in light of the ongoing challenging environment in the financial
markets.

 

Sustainability

Benchmark's mission is to drive sustainability in aquaculture.  In alignment
with our mission, sustainability is front and centre in our strategy and our
operations. Our products are designed to deliver improved yield and animal
welfare, improving resource efficiency and reducing environmental impact. In
addition, we manage our own operations responsibly with an ambitious
commitment to energy transition. In 2022, we made substantial progress towards
our Net Zero goals by developing a comprehensive emissions reduction programme
for our Thailand facility centred around the installation of solar panels
which commenced in 2022. In addition, during the year we conducted a climate
risk assessment across the Group for the first time representing an important
step towards TCFD (Task Force on Climate-related Financial Disclosures)
compliance in 2023.

 

Board

On 29 November 2021, the Board appointed Atle Eide as Non-Executive Director.
Given Atle's previous role as a director of Kverva AS, a significant
shareholder in the Company, he is not deemed an independent director. Atle has
extensive experience in the seafood industry including in his former roles as
Chairman of Salmar ASA and CEO of Mowi ASA, and as an investor, bringing value
to the Board.

 

Regular Board evaluation is an important element in maintaining high standards
of corporate governance and Board effectiveness. In 2022, the Board conducted
an internal evaluation exercise. The results, which were reviewed at the
September 2022 Board meeting, confirmed that the Board continues to perform
effectively and with a high degree of Director engagement.

 

Board meetings were held at various Group locations during the year, enabling
the Directors to interact broadly with our people, promoting engagement and an
understanding of local cultures.

 

Euronext Growth Listing

During the year, we communicated our intention to pursue a listing in Oslo as
the world's largest seafood-focused market. Our decision followed extensive
consultation with shareholders, concluding that the Company would benefit from
a listing in Oslo to expand its access to a global base of specialist seafood
investors and analysts and to improve liquidity in our shares.

 

The Company's plan to launch a dual-listing on Euronext Growth Oslo before the
end of the calendar year is well progressed.  The dual-listing represents a
first step towards a listing on the Oslo Stock Exchange (Oslo Børs), the
world's leading listed venue for seafood and aquaculture companies.  The
Board intends to uplist the Company to the Oslo Børs from Euronext Growth
Oslo in the first half of the calendar year 2023. In tandem, we intend to
consult with shareholders on whether to maintain the admission of the
Company's shares to trading on AIM. The intended dual listing on Euronext
Growth Oslo and the uplisting to the Oslo Børs are both subject to market
conditions.

 

In connection with its proposed admission to Euronext Growth Oslo, Benchmark
has today announced the terms of a potential private placement and retail
offering in Norway, representing in aggregate 5% of the Company's enlarged
issued share capital.

 

Looking ahead

While macroeconomic conditions remain challenging as we enter 2023 with high
levels of cost inflation and interest rates affecting consumer spend,
Benchmark has started the year positively and is prepared to meet the
challenges of an inflationary environment through a combination of price
increases and operational efficiencies to mitigate inflationary pressure.
Moreover, the Company enters 2023 with good momentum, and with a clear
strategy that will help deliver continued growth and progress towards
sustainable profitability and cash generation.

 

Longer term, Benchmark is well placed to deliver growth and attractive
shareholder returns. The Company is well invested, with multiple, visible
growth opportunities underpinned by existing infrastructure. This, together
with Benchmark's leading market positions and the megatrends driving the
aquaculture industry, give us confidence in the future.

 

Our strong performance this year could not have been achieved without the
efforts of the 800+ people who make up this great company. Their hard work,
integrity and expertise have shone through, and on behalf of the Board, I want
to thank them for everything they have done, and continue to do, for
Benchmark. I also want to thank and acknowledge our shareholders and other
stakeholders for their continued support.

 

Peter George

Chairman

 

 

Chief Executive Officer's Review

 

Sustained growth and strategic delivery

Benchmark delivered excellent growth in revenue and Adjusted EBITDA in FY22,
building on its track record of continuous quarterly improvement since the
restructuring was completed in FY20. Revenues grew by 27% to £158.3m in the
year, and Adjusted EBITDA excluding fair value movements from biological
assets grew by 83% to £29.6m. On a constant exchange rate basis, Group
revenue and Adjusted EBITDA excluding fair value movements, were up 21% and
76%, respectively. Since the end of FY20, we have increased revenues by 50%
and Adjusted EBITDA by 115%.

 

Despite the strong revenue growth and the progress in our underlying
profitability, the Group reported a loss before tax of £23.2m, (2021: loss of
£9.2m). This is due to a  £11.5m increase in depreciation principally
related to the leased vessels used in the CleanTreat® operations and an
increase in finance costs due to higher interest rate charges and non-cash
movements associated with the accounting for the refinancing of our
pre-existing NOK bond. Total loss for the year was £30.5m (FY21: £11.6m).

 

Trading and operational performance was strong in our three business areas and
all reported a significant increase in revenues and Adjusted EBITDA. Advanced
Nutrition continued its growth trend with revenues up by 14%; Genetics
increased revenues by 24%, benefitting from strong demand for our salmon eggs,
which we were able to fulfil through our recent investment in a new bio-secure
incubation centre in Iceland; and Health reported 157% growth in revenues,
benefitting from the launch of its sea lice solution, Ectosan® Vet and
CleanTreat®. While the commercialisation of Ectosan® Vet and CleanTreat® is
still in the initial phase, we now have three well-performing and growing
business areas with a visible path to Group profitability and cash generation.

 

We maintained our ongoing financial discipline on costs, investment and cash.
Operating costs and R&D were £51.4m, a 14% increase from the prior year
due to higher activity levels and cost inflation. Our ongoing cost control,
together with higher asset utilisation resulted in an Adjusted EBITDA margin
(excluding fair value movement from biological assets) of 19% (FY21: 13%).
Capex during the year totalled £10.8m (FY21: £18.0m) reflecting our new
investment discipline and completion of investments to support our main growth
vectors. Our main investment was the construction of a new incubation centre
for salmon eggs in Iceland which allows us to meet seasonal periods of peak
demand. This was particularly welcome this year when our customers experienced
a shortage of supply in our market.

 

By business area, Genetics reported revenues of £58m, 24% above last year
driven primarily by higher salmon egg sales. Adjusted EBITDA before fair value
movement in biological assets of £14.4m was 75% above last year (FY21:
£8.2m).  Strategically, we continued to build on our stronghold in salmon,
covering all production paradigms and producing regions. In addition, our
focus was on the launch of our SPR shrimp genetics in Asia and the Americas,
an important growth vector for the Group in the coming years. Innovation is a
key driver of our success in Genetics and during the year we strengthened our
team with the appointment of Dr. Ross Houston as Director of Innovation for
our Genetics business and Chair of our Group Innovation Board.

 

Advanced Nutrition reported revenues of £80.3m, 14% ahead of FY21 driven by
increased sales in all product areas - Artemia, Health and Diets. Adjusted
EBITDA of £19.0m was 38% up on the prior year (FY21: £13.8m). We continued
to capitalise on our enhanced commercial focus and structure and on our
efforts to improve our operations to drive efficiency and margins. This
included the closure of our trial facility in Thailand moving to more
effective solutions in partnership with external providers.

 

In Health we reported revenues of £20.1m, (FY21: £7.8m) as a result of
increased Ectosan® Vet and CleanTreat® sales following the commercial launch
at the end of last year. Adjusted EBITDA was £0.1m (FY21: loss £2.7m). The
roll-out of Ectosan® Vet and CleanTreat® is one of the Group's key strategic
priorities and we made further progress during the year, increasing adoption
of the new solution in the market. In addition, we reached important
milestones towards optimising our solution. Treatment times were reduced, a
marketing extension for a second re-use of treatment water was obtained and we
continue to work with our customers on new configurations for our CleanTreat®
systems adapted to our customer's infrastructure.

 

Strategic delivery

Benchmark's strategy is directed at becoming the leading aquaculture
biotechnology company driving sustainability and delivering attractive
shareholder returns. Our strategy represents a roadmap to achieve this and has
three main elements:

·  maximising the opportunity in our established business through a
proactive commercial effort and continuous operational improvement,
benefitting from structural growth in the industry

·   extending our platform through additions to our product offering and
geographic expansion within our core areas

·    pursuing add-on opportunities within our core areas and applying
disciplined return parameters

 

At the beginning of 2022, we set out five strategic Group priorities in areas
that will drive growth and profitability for the Group. These were the
roll-out of Ectosan® Vet and CleanTreat®, the commercialisation of our
shrimp genetics, regaining leadership in Artemia within our Advanced Nutrition
business and delivering ESG and People agendas that are aligned to our mission
and that support our new performance-driven culture. This clear strategic
focus enables us to direct resources and monitor progress. Overall, progress
in all areas was positive in 2022.

 

As mentioned above we made important strategic progress in the roll-out of our
Ectosan® Vet and CleanTreat® solution.

 

Our SPR shrimp in Genetics was commercially launched in the year with growing
sales albeit from a small initial base. Our leading position in the shrimp
market through our Advanced Nutrition business creates an important synergy
facilitating market entry.

 

In Advanced Nutrition, our priority for FY22 was to regain a leadership
position in the global Artemia market following a period of oversupply which
resulted in lower prices in the market affecting our premium positioning.
Through a renewed commercial effort brought about by a management change in
the business, we have successfully recovered our position and gained momentum
for the future.

 

Looking forward to 2023, our Group priorities represent a continuation of our
current effort including the roll-out of Ectosan® Vet and CleanTreat® and
maintaining our leadership position in Advanced Nutrition across our three
product areas. In Genetics, our focus will be on becoming the supplier of
choice for salmon eggs across all markets while continuing our work to
commercialise our shrimp genetics.

 

'One Benchmark' culture

One of our key focus areas over the last two years has been to create a
stronger, more aligned group to drive commercial performance and realise
synergies and efficiencies. The primary engine of this culture change is a
strategic priority framework working alongside a performance management
framework with our values to guide our behaviour.

 

This unified culture has allowed us to drive further integration by combining
functions and establishing cross-group initiatives which are delivering
results. An example of this is the combination of the marketing and commercial
functions around species allowing us to become more customer-centric.

 

Looking forward

We have had a good start to the year and there is good momentum in the
business. Cost inflation and other macroeconomic pressures will continue to be
a feature across the world in 2023 and we are not immune. However, we have a
well diversified, balanced business which creates resilience to challenges in
individual markets as well as opportunities. In addition, we will continue to
proactively mitigate potential pressure on our business and our margins
through pricing, supplier management and operational improvements. The
recently announced change in the tax regime for aquaculture producers in
Norway is expected to have a marginal direct effect on our business.

 

Looking further into the future, Benchmark is uniquely positioned in an
industry that is structurally growing and driven by multiple megatrends. This
creates significant opportunity for growth and increasing returns for
shareholders in the near and medium term and for many years to come.

 

Trond Williksen

Chief Executive Officer

 

 

Financial Review

 

Strong and positive performance in the year

FY22 has been a year where our focus on commercial execution has paid off.
With all three business areas now commercially focused, we have delivered
growth across the board and have been able to consistently deliver progress on
our strategic objectives. We have been able to leverage off the investments
made in FY21 to meet demand in the market within our Genetics business area.
We have continued to generate sales growth above market growth , albeit aided
by forex tailwinds from a strong US dollar in Advanced Nutrition, and have had
a full year of Ectosan®Vet and CleanTreat® sales moving Health from being a
development business area to a commercial one.

 

Overview of reported financial results

During 2022, the Group's focus was on continuing to deliver a strong
commercial result and advancing its strategic priorities.

 

Advanced Nutrition continued a track record of strong commercial focus in
2022. Genetics also experienced strong sales in the year and with a full year
of Ectosan® Vet and CleanTreat® sales in Health this resulted in an increase
in Group revenue of 27% to £158.3m in the year (2021: £125.1m). This
increase in sales meant that Gross Profit increased to £83.1m (2021:
£65.6m). Gross Margin was flat at 52% (2021: 52%). Using the same foreign
exchange rates experienced in 2021 (constant currency(5)) revenue increased by
21%.

 

 As Reported (£m unless otherwise stated)   2022    2021    % AER   % CER**
 Revenue                                    158.3   125.1   27%     21%
 Operating loss                             (7.9)   (5.4)   (46%)   (61%)
 Loss before tax                            (23.2)  (9.2)   (152%)  (167%)
 Loss for the period                        (30.5)  (11.6)  (163%)  (168%)
 Basic loss per share (p)                   (4.60)  (1.93)  (138%)  -

 

** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

 

 

 Adjusted Measures (£m unless otherwise stated)   2022    2021    % AER  % CER**
 Gross profit                                     83.1    65.6    27%    22%
 Gross profit %                                   52%     52%     -      -
 Adjusted EBITDA(1)                               31.2    19.4    60%    54%
 Adjusted EBITDA(1) margin %                      20%     16%     -      -
 Adjusted Operating Profit(2)                     9.1     10.8    (15%)  (23%)
 Net debt(3)                                      (73.7)  (80.9)  9%     -

 

** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

 

Business area performance

We continued to manage costs across the Group very closely. Operating costs
increased by 17% to £44.7m (2021: £38.2m) due to the investment in new
growth areas, mainly the ramp-up of activities for the launch of Ectosan®Vet
and CleanTreat® and increased activity post the pandemic. Expensed R&D
decreased by 5% to £6.7m (2021: £7.0m).

 

Adjusted EBITDA increased by 60% to £31.2m (2021: £19.4m) driven by
increased sales in Advanced Nutrition, a strong finish to the year in Genetics
and a full year of commercial activities in Health for Ectosan®Vet and
CleanTreat® as well as ongoing cost control.

 

Adjusted measures

We continue to use adjusted results as our primary measures of financial
performance. We believe that these adjusted measures enable a better
evaluation of our underlying performance. This is how the Board monitors the
progress of the Group.

 

We use growth at constant exchange rate metrics when considering our
performance, whereby currency balances are retranslated at the same exchange
rate in use for the prior year to illustrate growth on a currency like for
like basis.

 

In line with many of our peers in the sector, we highlight expensed R&D on
the face of the income statement separate from operating expenses.
Furthermore, we report earnings before interest, tax, depreciation and
amortisation ("EBITDA") and EBITDA before including exceptional and
acquisition- related items ("Adjusted EBITDA"). The activities of the Group's
equity accounted investees are closely aligned with the Group's principal
activities, as these arrangements were set up to exploit opportunities from
the Intellectual Property ("IP") held within the Group. As a result, to ensure
that adjusted performance measures are more meaningful, the Group's share of
the results of these entities is included within Adjusted EBITDA. We also
report this adjusted measure after depreciation and amortisation of
capitalised development costs ("Adjusted Operating Profit") as the Board
considers this reflects the result after taking account of the utilisation of
the recently expanded production capacity. In addition, in line with the
Salmon industry, we also report AEBITDA excluding fair value uplift under IAS
41. Available liquidity, being cash and undrawn facilities, is an important
metric for management of the business as it gives a measure of the available
liquid funds and is also a key financial covenant in the Group's main debt
facilities.

 

Genetics

Genetics delivered good growth in revenue driven by sales of salmon eggs where
volumes increased by 20% to 291 million eggs. Revenues of £58.0m were up 24%
(2021: £46.8m), +21% in constant currency.

 

Demand for eggs in Norway increased by 23% during the year, which we were able
to supply due to the increased capacity in our new incubation house in
Iceland. We also saw increased demand from all other territories in the year.
This resulted an increase in revenue from salmon eggs of 24% to £38.3m (2021:
£30.9m).

 

In non-product based revenue streams, Genetics Services continued to deliver
in the year reflecting the strength and depth of expertise of our Genetics
team and our IP in the business, contributing £1.3m (2021: £1.3m). Revenues
from harvested fish were aided by increased salmon prices producing harvest
income in the year of £8.5m (2021: £6.2m). Royalties earned from use of our
genetic IP fell in the year, with sales down to £0.8m (2021: £1.0m) as the
expected unwind of contracts continues for the next year. Revenues from other
products totalled £9.1m (2021: £7.4m).

 

Gross profit increased by 24% in 2022 to £32.0m (2021: £25.9m) and gross
margin remained unchanged at 55%. Increased  gross profit from the core
salmon business was offset by losses in the newly launched SPR shrimp and
tilapia, and the non-cash fair value increase in biological assets fell by 52%
in 2022 to £1.6m (2021: £3.3m).

 

Shrimp and tilapia, both of which are areas of investment, delivered combined
Adjusted EBITDA losses in the period of £3.1m (2021: £1.4m). The shrimp loss
of £1.7m (2021: £0.9m) followed the ceasing of capitalising costs after the
commercial launch of SPR shrimp in the year. We capitalised costs of £1.0m in
2022 related to development of the shrimp nucleus before it launched
commercially. The loss in Tilapia was driven by the capacity expansion being
delayed due to COVID and a one-off £0.4m loss related to a provision for
committed running costs, over and above the lease obligations, on a production
site which is no longer used.

 

R&D spend was lower and operating costs were higher than 2021 by £0.6m
and £2.2m respectively as the business grew. R&D reduced due to good cost
optimisation in this area. R&D activities in this business area are
focused on developing the traits of growth, disease resistance and sea lice
resistance by selecting the best performing animals from each generation
supported by cutting edge genetic technologies. The search for markers for new
traits that can be included in the breeding programme continues.

 

The share of profits/losses from the equity accounted investees relates
primarily to the joint venture with Salmar Genetics AS which delivered a share
of loss of £0.5m (2021: loss of £0.6m).  In both 2022 and 2021, the joint
venture suffered a biological event which drove the losses.

 

Genetics has continued to establish its facility in Chile and with overall
AEBITDA losses of £3.4m and £0.6m invested in capex in this new facility in
2022 (2021: £2.6m and 1.3m). The facility has potential production capacity
of 50 million eggs and is currently utilising capacity of around 30 million
eggs. During the year we sold 4 million eggs.

 

All these factors contributed to increased AEBITDA of £16.0m (2021: £11.5m)
and AEBITDA margin of 28% (2021: 25%). AEBITDA excluding fair value increased
by 75% to £14.4m, an AEBITDA margin of 25% (2021: 17%).

 

Advanced Nutrition

Throughout 2022, Advanced Nutrition delivered a strong performance driven by
continued commercial focus. As a result, revenues in Advanced Nutrition
increased by 14% in the year (7% at CER). This is notable as some key markets
continued to be impacted by COVID-19 and the business faced significant
logistical challenges as a result of the pandemic. The strong commercial focus
has allowed us to continue to strengthen our position and take increased
market share.

 

In 2022, 73% of our revenues derived from shrimp with the balance 27% of
derived from the Mediterranean sea bass and sea bream sector.

 

By product area, we drove growth in all product areas. Artemia grew revenues
by 7% (at CER) to £37.1m, followed by diets up 7% (at CER) to £35.1m. Health
which covers our probiotic and environmental pond management portfolio grew
revenues by 6% (at CER) to £8.1m.

 

The increase in sales of £9.8m resulted in an increase in gross profit of
£6.6m and drove the gross margin up from 51% to 53%. This increase in margin
was offset in part by an increase in operating costs as we grew the business,
but there continued to be good cost control throughout this year. This led to
Advanced Nutrition reporting AEBITDA of £19.0m (2021: £13.8m) and an
increase in AEBITDA margin from 20% to 24%.

 

Within this business area, an important barrier to entry is the access to GSL
Artemia where we, through our relationship with the Great Salt Lakes
Cooperative have access to 44% of the annual harvest of Artemia from the Great
Salt Lakes. Whilst the harvest can vary from year to year and we saw very high
harvest levels in 19/20, the last two harvests were lower;  the 20/21 harvest
was 1,168 metric tonnes and the 21/22 harvest was 1,104 metric tonnes which
are considered normal harvest levels.

 

Health

Health reported revenue of £20.1m (2021: £7.8m) reflecting the first full
year of sales of Ectosan®Vet and CleanTreat® of £14.8m of which £2.5m
relates to revenue for vessel-related costs and a marginal increase in sales
of our existing sea lice treatment, Salmosan® Vet of £5.4m (2021: £5.1m).

 

Gross profit increased by £4.9m to £8.6m, a margin of 43%, with the launch
of Ectosan®Vet and CleanTreat® combined with increased margins from
Salmosan® Vet.

 

During the year, the focus of this business area was to launch Ectosan®Vet
and CleanTreat® in Norway. The first vessel launched in August 2021, with the
second vessel launching in December 2021. These activities drove an increase
in operating costs to £8.1m (2021: £6.2m) Adjusted EBITDA for the business
area was £0.1m (2021: £2.7m).

 

Cost Inflation

As noted earlier, cost control remains of significant importance in Benchmark
and in the current cost environment becomes even more so. During the year, we
focussed on a number of areas to mitigate cost inflation. In Nutrition, the
Operations team focused on ensuring lean production and with better volumes,
getting better cost per units through to support margin. The procurement team
were consistently challenged to maintain or get better pricing for raw
materials. From an energy perspective, we have access to lower cost energy in
both Norway and Iceland where we have Genetics production facilities and we
have also commenced the plan to put solar panels on our facility in Thailand.
Whilst we are not immune from inflation, we as a business seek to use multiple
ways to mitigate this as we move forward.

 

Exceptional items

Items that are material because of their nature whose significance is
sufficient to warrant separate disclosure and identification within the
consolidated financial statements are referred to as exceptional items. The
separate reporting of exceptional items helps to provide an understanding of
the Group's underlying performance.

 

Exceptional expenses were fully offset by exceptional credits in the year.
Exceptional expenses related to legal and professional costs in relation to
the proposed dual listing on the Oslo exchange of £0.8m, and restructuring
costs of £0.4m including those relating to a legal dispute within a divested
business, and costs relating to the closure of the Thai research centre in
Advanced Nutrition. These costs were offset by a credit of £1.2m relating to
additional contingent consideration received in the period following the
disposal of Aquaculture UK on 7 February 2020 and Improve International on 23
June 2020.

 

Depreciation, amortisation and impairments

Depreciation and impairment of tangible assets was £19.9m (2021: £8.4m),
with depreciation charge of £19.9m (2021: £8.5m) and impairment reversal of
£nil (2021: £0.1m). The depreciation charge in the year increased due to the
launch of CleanTreat® where the vessels are right-of-use assets held under
lease agreements. In total, depreciation and impairment charges on leased
assets under IFRS 16 was £11.3m (2021: £3.3m).

 

Amortisation and impairments of intangible assets totalled £19.2m (2021:
£16.3m). The amortisation charge includes £2.2m (2021: £0.3m) relating to
capitalised development following commercialisation of Ectosan®Vet and
CleanTreat® and SPR shrimp.

 

Research and development

 £m                                 Expenses                      Total expensed and capitalised
                                    2022  As % of  2021  As % of  2022      As % of   2021      As % of sales

sales

                                                         sales              sales
 Expensed R&D by business area
 Genetics                           4.3   7%       4.9   10%      5.3       9%        6.8       15%
 Advanced Nutrition                 2.0   2%       1.9   3%       2.1       3%        2.2       3%
 Health                             0.4   2%       0.2   3%       1.0       5%        2.9       36%
 Total research and development     6.7   4%       7.0   6%       8.4       5%        11.8      9%

 

 

Expensed R&D activities decreased in the year by £0.3m with Genetics
having good cost optimisation in this area while continuing to focus on
improvements in the breeding nucleus. Health spending remained low due to
their significantly reduced R&D programmes. Genetics' research is focused
around continually developing new disease and parasitic resistant traits as
well as growth traits which we can breed into our products. Advanced
Nutrition's focus is on expanding our product portfolio and driving growth
through product improvements.

 

Other operating costs

 £m                                   2022  As % of  2021  As % of

                                            sales          sales
 Operating Expenses by Business Area
 Genetics                             11.1  19%      8.9   19%
 Advanced Nutrition                   21.5  27%      19.9  28%
 Health                               8.1   41%      6.2   79%
 Corporate (net)                      4.0            3.2
 Total operating expenses             44.7  28%      38.2  31%

 

 

Other operating costs increased from £38.2m in 2021 to £44.7m in 2022. The
increase in costs include increased costs in Health as we had a full year of
commercial launch of Ectosan®Vet and CleanTreat® and higher costs as we
commercially launched Chile and SPR shrimp and continued to grow in Nutrition.

 

 

Net finance costs

 £m                                        Analysis
                                           2022   2021
 Net Finance expenses
 Interest Income                           (0.3)  (0.1)
 Foreign Exchange losses/(gains)           (2.8)  (2.8)
 Interest on bond and bank debt            6.2    6.0
 Amortisation of deferred financing fees   1.9    1.0
 Penalty for early settlement of the bond  1.6    -
 Movements of cash flow hedges             7.0    (1.4)
 Finance lease interest                    1.7    1.1
 Total net finance expenses                15.3   3.8

 

 

The Group incurred net finance costs of £15.3m during the year (2021:
£3.8m). Included within this was interest charged on the Group's
interest-bearing debt facilities of £9.7m (2021: £6.9m) of which £1.6m
related to the early redemption penalty for the settlement of the NOK bond and
with a further £1.9m of this being amortisation of the deferred finance costs
(2021: £1.0m). Net foreign exchange gains of £2.8m (2021: net gain of
£2.8m) arose due to the movement in exchange rates on intercompany loans and
external debt. Movements on the cash flow hedges associated with the Groups
NOK bond debt resulted in charges of £7.0m  (2021: gain of £1.4m).

 

Statutory loss before tax

The loss before tax for the year at £23.2m is higher than the prior year
(2021: loss of £9.2m).  This was a result of the positive trading result
offset by the increased depreciation on right-of-use assets and amortisation
of intangibles following the launch of Ectosan® Vet/CleanTreat® and SPR
shrimp, as well as higher net finance costs as discussed above.

 

Taxation

There was a tax charge on the loss for the year of £7.3m (2021: £2.4m),
mainly due to overseas tax charges in Genetics and Advanced Nutrition in
territories where no loss relief is available, partially offset by deferred
tax credits on intangible assets mainly arising on consolidation from
acquisitions.

 

Other Comprehensive Income

In addition to the loss for the year of £30.5m, a significant item to be
reclassified to the income statement related to foreign exchange
translation differences. The gain on this account was £47.2m. This gain
was driven by a strong USD impacting two main items, firstly the retranslation
of the foreign currency denominated subsidiary balance sheets in GBP at the
year end of £36.3m and the foreign exchange of £10.9m associated with items
which are designated as net investment hedges or internal loans which are
deemed to be equity and as such the exchange associated with these goes
directly to other comprehensive Income.

 

Reported loss for the year

The loss for the year was £30.5m (2021: loss of £11.6m).

 

Earnings per share

Basic loss and diluted loss per share were both 4.60p (2021: loss per share
1.93p). The movement year on year is due to the movement in the result as well
as the increase in the weighted average number of shares in issue of 28m.

 

Dividends

No dividends have been paid or proposed in either 2022 or 2021 and the Board
is not recommending a final dividend in respect of the year ended 30 September
2022.

 

Biological assets

A feature of the Group's net assets is its investment in biological assets,
which under IAS 41 are stated at fair value. At 30 September 2022, the
carrying value of biological assets was £46.7m (2021: £38.4m). This increase
is due principally to the increase in the biomass of broodstock as we continue
to expand production at Salten and Chile and increased eggs available for sale
in FY23. The fair value uplift on biological assets included in cost of goods
for the year was £1.6m (2021: £3.3m).

 

Intangibles

Additions to intangibles were £1.9m (2021: £5.0m) with the main area of
investment being capitalised development costs which in the year decreased by
£3.1m to £1.7m (2021: £4.8m). R&D costs related to products that are
close to commercial launch have to be capitalised when they meet the
requirements set out under IAS 38. In this financial year, the main
development projects capitalised were as follows:

 

·    Ectosan®Vet/CleanTreat® (£0.6m)

·    SPR shrimp (£1.0m)

·    Patents for genetics (£0.2m)

·    Live food alternative diets (£0.1m)

 

Capital expenditure

During 2021, we invested in a number of growth initiatives and in 2022 there
remained some spend to complete them. The Group incurred tangible fixed asset
additions of £10.8m (2021: £18.0m) broken down as follows:

 

·    Health:         £2.6m

·    Genetics:     £5.6m

·    Nutrition:    £2.6m

 

Within Health, there was an investment in a third CleanTreat® unit and
finalising the mobilisation of the second vessel on which the second
CleanTreat® units are situated. During the year, this third CleanTreat® unit
was reclassified to inventory as it is intended to be used in the new business
model whereby the units are sold to customers rather than owned by us. Capex
associated with our Genetics business was £5.6m where we finished the new
incubation house for our Icelandic facility (£2.3m) and commenced building
new tanks at Salten to support ramping up to the 150 million egg capacity at
that facility which will continue in FY23 (£1.2m) and we continue to invest
in our other growth initiatives SPR Shrimp and Tilapia in the US. In Nutrition
we continued to invest in the two manufacturing facilities to support
continued growth.

 

Cash flow, liquidity and net debt

 Movement in net debt                                                     £m
 Net debt at 30 September 2021                                            (80.9)
 Cash generated from operations excluding working capital and taxes paid  30.3
 Movement in working capital                                              (12.0)
 Capital expenditure                                                      (12.7)
 Other investing activities                                               (0.2)
 Foreign exchange on cash and debt                                        10.5
 Interest and tax                                                         (17.0)
 Proceeds from previous year disposals of subsidiaries                    1.5
 New leases (IFRS 16)                                                     (11.5)
 Shares issued                                                            20.2
 Other non-cash movements                                                 (1.9)
 Net debt at 30 September 2022                                            (73.7)

 

 

Cash flow

With improved trading in all business areas, we saw strong cash generated from
operations of £30.3m (2021: £22m). This also drove higher working capital
levels and taxes, leading to net cash flows generated from operating
activities of £10.8m (2021: £5.8m). Capital expenditure, both intangible and
tangible, showed a significant decrease of £10.0m to £12.7m (2021: £22.7m)
as we worked to moderate our capex and finished off the investment in some of
the growth initiatives, primarily the incubation house in Iceland.

 

Working capital

Working capital has grown in the period driven by a number of factors. As the
dollar strengthened, we can see the impact on the balance sheet as noted above
in the other comprehensive income section and this increased the working
capital balances at 30 September 2022, but working capital did grow during
FY2022.

 

We noted earlier the increase in biological assets within the genetics areas.
Other Inventories grew in Nutrition as we had more GSL Artemia in inventory
than previous years to ensure it was available in all locations.

 

In Health, we had transferred the CleanTreat® equipment into Inventory
resulting in Health inventory increasing by £3.4m.

 

Trade Debtors and creditors, of course, increased as a result of increased
sales but trade debtors only increased slightly as a % of sales from 19% to
20% in the year. Similarly, trade payables were only slightly higher than last
year.

 

A significant amount of cash is tied up with the working capital of the group
and focus continued to be on releasing that investment in the years to come.

 

Refinancing and borrowing facilities

The Group had a NOK 850m senior secured floating rate listed bond which was
due to mature in June 2023 with a coupon of 5.25% above three months Norwegian
Interbank Offered Rate ("NIBOR"). The Group also has a USD 15m revolving
credit facility ("RCF") which was due to mature in December 2022 and had £4m
drawn at 30 September 2022. The interest rate on the facility is between 3%
and 3.5% above LIBOR depending on leverage.

 

The Company successfully completed a new senior unsecured green bond issue of
NOK 750 million, with an expected maturity date of 27 September 2025. The bond
has a coupon of three months NIBOR* + 6.5% p.a. with quarterly interest
payments.

 

There are other borrowing facilities held within Benchmark Genetics Salten AS
which were put in place to fund the building of the Salten salmon eggs
facility totalling NOK 227.5m (£18.8m) (2021: NOK 246m (£20.9m)), which are
ringfenced without recourse to the other parts of the Group. Interest on these
other debt facilities ranges between 2.65% and 5% above Norwegian base rates.
In addition, a working capital facility of NOK 20.0m (renewal annual in March)
and an overdraft of NOK 17.5m (maturity December 2022) were in place for use
solely by Benchmark Genetics Salten AS. These  facilities are undrawn (2021:
undrawn).

 

Subsequent Events

Subsequent to the year end, on 21 November 2022, the company successfully
refinanced the RCF facility with a new facility of £20m. The interest rate on
the new RCF was between 2.5% and 3.25% with a maturity of June 2025. In
addition, the term loan facility outstanding balance and the overdraft
facility provided by Nordea were refinanced into one facility on 1 November
2022 totalling NOK179.5m with a maturity date of January 2028. The margin on
the new facility is 2.5%.

 

Cash and total debt

 Net debt                        £m
                                 2022    2021
 Cash                            36.4    39.5
 NOK 750m bond (2021: NOK 850m)  (61.1)  (75.5)
 Other borrowings                (22.8)  (20.9)
 Lease liabilities               (26.2)  (24.0)
 Net debt                        (73.7)  (80.9)

 

 

The RCF facility combined with the year-end cash balance of £36.4m (2021:
£39.5m) means the Group had total liquidity of £45.8m (2021: £50.6m). This,
while utilising tight cost and cash control, is expected by the Directors to
provide the Group with sufficient liquidity to fund the investment and working
capital to crystalise the growth opportunities which are part of the strategic
priorities of the Group and provide adequate headroom.

 

Equity raise

In November 2021, £20m net proceeds were raised through a placing to provide
the Company with additional headroom to maintain this momentum and to continue
to fund its ongoing growth initiatives.

 

Oslo listing

During FY2021, the Board commenced a review of our capital structure in the
context of the approaching maturity of the main facilities as noted above and
with regard to funding in the short term for investment opportunities to
accelerate business area growth. As a result the company continues to progress
towards a listing on Euronext Growth Oslo by the end of calendar year 2022. As
previously announced the Company intends to uplist to the Oslo Børs, the
leading seafood and aquaculture market globally, in H1 of calendar year 2023.
The timing of both the listing on Euronext Growth Oslo and intended uplist to
the Oslo Børs is subject to market conditions.

 

Covenants

Banking covenants for the NOK bond and RCF exist in relation to liquidity and
an 'equity ratio'. Liquidity, defined as 'freely available and unrestricted
cash and cash equivalents, including any undrawn amounts under the RCF', must
always exceed the minimum liquidity value, set at £10m. Available liquidity
at 30 September 2022 is £45.8m (2021: £50.6m). The equity ratio, defined as
'the ratio of Book Equity to Total Assets' must always exceed 40%. The equity
ratio at 30 September 2022 was 61% (2021: 58%). In addition, an equity to
asset ratio covenant exists for the Benchmark Genetics Salten AS debt with a
target threshold of 40%, this equity to asset ratio was 51.3% at 30 September
2022 (2021: 46.2%).

 

Going concern

As at 30 September 2022 the Group had net assets of £323.3m (2021: £279.6m),
including cash of £36.4m (2021: £39.5m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £30.5m (2021: £11.6m).
As at 30 September 2022 the Company had net assets of £346.6m (2021:
£336.2m), including cash of £3.2m (2021: £9.0m) as set out on the Company
Balance Sheet. The Company made a loss for the year of £16.5m (2021: £3.9m).

 

As noted in the Strategic Report, we have seen a year of strong performance
following an extended period impacted by COVID-19, with improvements
throughout the year in all of our three business areas. The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.

 

The year ended with the successful refinancing of its NOK 850 million bond
which was due to mature in June 2023 with the issue of a NOK 750 million
unsecured green bond maturing in 2025. This was achieved against a backdrop of
challenging macroeconomic and market conditions and places the Group in a much
stronger position in light of the ongoing market environment. Additionally,
following the year end, the USD15m RCF was refinanced by a new £20m RCF on 21
November 2022 with a June 2025 maturity. Furthermore, our NOK 216m loan
facility (which had NOK 165.6m outstanding at the year end) which was set to
mature in October 2023 was combined with our NOK 17.5m overdraft facility into
a new loan facility of NOK 179.5m on 1 November 2022, with a new maturity date
in a further 5 years no later than 15 January 2028. Following all of these
refinancing transactions, the Directors are satisfied there are sufficient
facilities in place during the assessment period.

 

The global economic environment has recently experienced turbulence largely as
a result of the conflict in Eastern Europe with supply issues in a number of
industries impacted and inflation at high levels. Against this backdrop, the
Group shows resilience against these pressures in its forecasts, with
financial instruments in place to fix interest rates and with opportunities
available to mitigate globally high inflation rates, such that even under all
of the above scenario analysis, the Group has sufficient liquidity and
resources throughout the period under review whilst still maintaining adequate
headroom against the borrowing covenants. The Directors therefore remain
confident that the Group has adequate resources to continue to meet its
liabilities as and when they fall due within the period of 12 months from the
date of approval of these financial statements. Based on their assessment, the
Directors believe it remains appropriate to prepare the financial statements
on a going concern basis.

 

 

Consolidated Income Statement

for the year ended 30 September 2022

 

                                                          Notes  2022       2021

                                                                 £000       £000
 Revenue                                                         158,277    125,062

 Cost of sales                                                   (75,149)   (59,477)
 Gross profit                                                    83,128     65,585
 Research and development costs                                  (6,691)    (7,010)
 Other operating costs                                           (44,661)   (38,221)
 Share of loss of equity-accounted investees, net of tax         (595)      (905)
 Adjusted EBITDA²                                                31,181     19,449
 Exceptional - restructuring/acquisition-related items    4      16         (184)
 EBITDA¹                                                         31,197     19,265
 Depreciation and impairment                                     (19,897)   (8,359)
 Amortisation and impairment                                     (19,161)   (16,283)
 Operating loss                                                  (7,861)    (5,377)
 Finance cost                                             3      (20,057)   (7,987)
 Finance income                                           3      4,741      4,185
 Loss before taxation                                            (23,177)   (9,179)
 Tax on loss                                                     (7,274)    (2,397)
 Loss for the year                                               (30,451)   (11,576)
 (Loss)/profit for the year attributable to:
 - Owners of the parent                                          (32,087)   (12,891)
 - Non-controlling interest                                      1,636      1,315
                                                                 (30,451)   (11,576)
 Earnings per share
 Basic loss per share (pence)                             5      (4.60)     (1.93)
 Diluted loss per share (pence)                           5      (4.60)     (1.93)

1       EBITDA - earnings before interest, tax, depreciation,
amortisation and impairment.

2       Adjusted EBITDA - EBITDA before exceptional and
acquisition-related items.

 

 

Consolidated Statement of Comprehensive Income

for the year ended 30 September 2022

 

                                                                       2022      2021

                                                                       £000      £000
 Loss for the year                                                     (30,451)  (11,576)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                              47,606    (9,929)
 Cash flow hedges - changes in fair value                              2,627     3,054
 Cash flow hedges - reclassified to profit or loss                     2,546     709
 Total comprehensive income for the year                               22,328    (17,742)
 Total comprehensive income for the year attributable to:
 - Owners of the parent                                                20,326    (19,329)
 - Non-controlling interest                                            2,002     1,587
                                                                       22,328    (17,742)

 

 

Consolidated Balance Sheet

as at 30 September 2022

 

                                                                   Notes  2022       2021

                                                                          £000       £000
 Assets
 Property, plant and equipment                                     6      81,900     78,780
 Right-of-use assets                                               7      27,034     25,531
 Intangible assets                                                 8      245,264    229,040
 Equity-accounted investees                                               3,113      3,354
 Other investments                                                        15         15
 Biological and agricultural assets                                10     20,878     21,244
 Non-current assets                                                       378,204    357,964
 Inventories                                                              29,813     20,947
 Biological and agricultural assets                                10     25,780     17,121
 Trade and other receivables                                       11     56,377     46,498
 Cash and cash equivalents                                                36,399     39,460
 Current assets                                                           148,369    124,026
 Total assets                                                             526,573    481,990
 Liabilities
 Trade and other payables                                          12     (44,324)   (46,668)
 Loans and borrowings                                              13     (17,091)   (10,654)
 Corporation tax liability                                                (10,211)   (5,634)
 Provisions                                                               (1,631)    (563)
 Current liabilities                                                      (73,257)   (63,519)
 Loans and borrowings                                              13     (93,045)   (109,737)
 Other payables                                                    12     (8,996)    (911)
 Deferred tax                                                             (27,990)   (28,224)
 Non-current liabilities                                                  (130,031)  (138,872)
 Total liabilities                                                        (203,288)  (202,391)
 Net assets                                                               323,285    279,599
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                            704        670
 Additional paid-in capital                                               420,824    400,682
 Capital redemption reserve                                               5          5
 Retained earnings                                                        (185,136)  (154,231)
 Hedging reserve                                                          (703)      (5,876)
 Foreign exchange reserve                                                 77,705     30,465
 Equity attributable to owners of the parent                              313,399    271,715
 Non-controlling interest                                                 9,886      7,884
 Total equity and reserves                                                323,285    279,599

 

The financial statements were approved and authorised for issue by the Board
of Directors on 30 November 2022 and were signed on its behalf by:

Septima Maguire

Chief Financial Officer

 

Company number: 04115910

 

 

Consolidated Statement of Changes in Equity

for the year ended 30 September 2022

 

                                                     Share     Additional paid-in share capital*  Other reserves  Hedging reserve  Retained earnings  Total attributable to equity holders of parent  Non-controlling interest  Total

                                                     capital                                                                                                                                                                    equity
                                                     £000      £000                               £000            £000             £000               £000                                            £000                      £000
 As at 1 October 2020                                668       399,601                            40,683          (9,651)          (142,170)          289,131                                         6,309                     295,440
 Comprehensive income for the year
 (Loss)/profit for the year                          -         -                                  -               -                (12,891)           (12,891)                                        1,315                     (11,576)
 Other comprehensive income                          -         -                                  (10,213)        3,775            -                  (6,438)                                         272                       (6,166)
 Total comprehensive income for the year             -         -                                  (10,213)        3,775            (12,891)           (19,329)                                        1,587                     (17,742)
 Contributions by and distributions to owners
 Share issue                                         2         1,081                              -               -                -                  1,083                                           -                         1,083
 Share-based payment                                 -         -                                  -               -                830                830                                             -                         830
 Total contributions by and distributions to owners  2         1,081                              -               -                830                1,913                                           -                         1,913
 Changes in ownership
 Acquisition of NCI                                  -         -                                  -               -                -                  -                                               (12)                      (12)
 Total changes in ownership interests                -         -                                  -               -                -                  -                                               (12)                      (12)
 Total transactions with owners of the Company       2         1,081                              -               -                830                1,913                                           (12)                      1,901
 As at 30 September 2021                             670       400,682                            30,470          (5,876)          (154,231)          271,715                                         7,884                     279,599
 Comprehensive income for the year
 (Loss)/profit for the year                          -         -                                  -               -                (32,087)           (32,087)                                        1,636                     (30,451)
 Other comprehensive income                          -         -                                  47,240          5,173            -                  52,413                                          366                       52,779
 Total comprehensive income for the year             -         -                                  47,240          5,173            (32,087)           20,326                                          2,002                     22,328
 Contributions by and distributions to owners
 Share issue                                         34        20,704                             -               -                -                  20,738                                          -                         20,738
 Share issue costs recognised through entity         -         (562)                              -               -                -                  (562)                                           -                         (562)
 Share-based payment                                 -         -                                  -               -                1,182              1,182                                           -                         1,182
 Total contributions by and distributions to owners  34        20,142                             -               -                1,182              21,358                                          -                         21,358
 Changes in ownership
 Total changes in ownership interests                -         -                                  -               -                -                  -                                               -                         -
 Total transactions with owners of the Company       34        20,142                             -               -                1,182              21,358                                          -                         21,358
 As at 30 September 2022                             704       420,824                            77,710          (703)            (185,136)          313,399                                         9,886                     323,285

 

 

Consolidated Statement of Cash Flows

for the year ended 30 September 2022

 

                                                                 Notes  2022      2021

                                                                        £000      £000
 Cash flows from operating activities
 Loss for the year                                                      (30,451)  (11,576)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment           8,602     5,017
 Depreciation and impairment of right-of-use assets                     11,295    3,342
 Amortisation and impairment of intangible fixed assets                 19,161    16,283
 (Profit)/loss on sale of property, plant and equipment                 (43)      46
 Finance income                                                  3      (319)     (1,442)
 Finance costs                                                   3      18,437    7,987
 Increase in fair value of contingent consideration receivable          (1,203)   -
 Share of loss of equity-accounted investees, net of tax                595       905
 Foreign exchange losses/(gains)                                        (3,985)   (1,800)
 Share-based payment expense                                            1,182     830
 Other adjustments for non-cash items                                   (276)     -
 Tax expense                                                            7,274     2,397
 Increase in trade and other receivables                                (8,511)   (8,178)
 Increase in inventories                                                (5,406)   (3,554)
 Increase in biological and agricultural assets                         (6,099)   (5,427)
 Increase in trade and other payables                                   6,946     5,547
 Increase in provisions                                                 1,058     -
                                                                        18,257    10,377
 Income taxes paid                                                      (7,447)   (4,587)
 Net cash flows generated from operating activities                     10,810    5,790
 Investing activities
 Purchases of investments                                               (378)     (578)
 Receipts from disposal of investments                                  1,544     9
 Purchases of property, plant and equipment                             (10,808)  (17,683)
 Purchases of intangibles                                               (205)     (225)
 Capitalised research and development costs                             (1,708)   (4,813)
 Proceeds from sale of fixed assets                                     220       112
 Interest received                                                      119       88
 Net cash flows used in investing activities                            (11,216)  (23,090)
 Financing activities
 Proceeds of share issues                                               20,737    750
 Share-issue costs recognised through equity                            (562)     -
 Acquisition of NCI                                                     -         (12)
 Proceeds from bank or other borrowings (net of borrowing fees)         67,939    -
 Repayment of bank or other borrowings                                  (74,874)  (3,106)
 Interest and finance charges paid                                      (9,629)   (7,699)
 Repayments of lease liabilities                                        (10,533)  (4,602)
 Net cash flows used in from financing activities                       (6,922)   (14,669)
 Net decrease in cash and cash equivalents                              (7,328)   (31,969)
 Cash and cash equivalents at beginning of year                         39,460    71,605
 Effect of movements in exchange rate                                   4,267     (176)
 Cash and cash equivalents at end of year                               36,399    39,460

 

 

The accompanying notes form part of the financial statements

 

 

1.     Basis of preparation

These audited results have been prepared on the basis of the accounting
policies which are to be set out in Benchmark Holdings Plc's annual report and
financial statements for the year ended 30 September 2022. Those policies have
been consistently applied to all the years presented unless otherwise stated.

 

These Group and parent company financial statements were prepared and approved
by the Directors in accordance with UK- adopted International Accounting
Standards in conformity with the requirements of the Companies Act 2006 as it
applies to companies reporting under those standards ("Adopted IFRS"). While
the financial information included in this preliminary statement has been
prepared on the basis of the requirements of IFRSs in issue, this statement
does not itself contain sufficient information to comply with IFRS.

 

The financial information set out above does not constitute the company's
statutory accounts for the years ended 30 September 2022 or 2021 but is
derived from those accounts. Statutory accounts for 2021 have been delivered
to the registrar of companies, and those for 2022 will be delivered in due
course. The auditor has reported on those accounts. The auditor's report for
2022 was (i) unqualified and (ii) did not contain a statement under section
498(2) or (3) of the Companies Act 2006. Their report for the accounts of 2021
was (i) unqualified, (ii) contained a material uncertainty in respect of
going concern to which the auditor drew attention by way of emphasis without
modifying their report and (iii) did not contain a statement under section
498(2) or (3) of the Companies Act 2006.

 

The financial statements are prepared on the historical cost basis except that
the following assets and liabilities are stated at their fair value: certain
financial assets and financial liabilities (including contingent consideration
receivable and derivatives) and biological assets measured at fair value.
Non-current assets and disposal groups held for sale are stated at the lower
of previous carrying amount and fair value less costs to sell.

 

Going concern

As at 30 September 2022 the Group had net assets of £323.3m (2021: £279.6m),
including cash of £36.4m (2021: £39.5m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £30.5m (2021: £11.6m).
As at 30 September 2022 the Company had net assets of £346.6m (2021:
£336.2m), including cash of £3.2m (2021: £9.0m) as set out on the Company
Balance Sheet. The Company made a loss for the year of £16.5m (2021: £3.9m).

 

As noted in the Strategic Report, we have seen a year of strong performance
following an extended period impacted by COVID-19, with improvements
throughout the year in all of our three business areas. The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan(®)Vet and CleanTreat(®)
offering. Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan(®) Vet and CleanTreat(®) through delayed
roll-out of the revised operating model for the service, together with
reductions in expected biomass treated and reduced treatment prices. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.

 

The year ended with the successful refinancing of its NOK 850 million bond
which was due to mature in June 2023 with the issue of a NOK 750 million
unsecured green bond maturing in 2025. This was achieved against a backdrop of
challenging macroeconomic and market conditions and places the Group in a much
stronger position in light of the ongoing market environment. Additionally,
following the year end, the USD15m RCF was refinanced with the agreement of a
new GBP20m RCF on 21 November 2022 with a maturity of June 2025. Furthermore,
our NOK 216m loan facility (which had NOK 165.6m outstanding at the year end)
which was set to mature in October 2023 was combined with our NOK 17.5m
overdraft facility into a new loan facility of NOK 179.5m on 1 November 2022,
with a new maturity date in a further 5 years no later than 15 January 2028.
Following all of these refinancing transactions, the Directors are satisfied
there are sufficient facilities in place during the assessment period.

 

The global economic environment has recently experienced turbulence largely as
a result of the conflict in Eastern Europe with supply issues in a number of
industries impacted and inflation at high levels. Against this backdrop, the
Group shows resilience against these pressures in its forecasts, with
financial instruments in place to fix interest rates and with opportunities
available to mitigate globally high inflation rates, such that even under all
of the above scenario analysis, the Group has sufficient liquidity and
resources throughout the period under review whilst still maintaining adequate
headroom against the borrowing covenants.

 

The Directors therefore remain confident that the Group has adequate resources
to continue to meet its liabilities as and when they fall due within the
period of 12 months from the date of approval of these financial statements.
Based on their assessment, the Directors believe it remains appropriate to
prepare the financial statements on a going concern basis.

 

2.     Segment information

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

-       Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.

-       Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

-       Health - following the divestment programme completed in the
previous year the segment now focuses on providing health products to the
global aquaculture market.

 

In order to reconcile the segmental analysis to the Consolidated Income
Statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

 

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy was
applied consistently throughout the current and prior period.

 

                                                                                                                  Inter- segment

                                                                       Advanced Nutrition                         sales

 Year ended 30 September 2022                               Genetics   £000                 Health    Corporate   £000            Total

                                                            £000                            £000      £000                        £000
 Revenue                                                    58,008     80,286               20,135    5,120       (5,272)         158,277
 Cost of sales                                              (25,971)   (37,733)             (11,544)  4           95              (75,149)
 Gross profit/ (loss)                                       32,037     42,553               8,591     5,124       (5,177)         83,128
 Research and development costs                             (4,329)    (1,990)              (372)     -           -               (6,691)
 Operating costs                                            (11,133)   (21,546)             (8,111)   (9,048)     5,177           (44,661)
 Share of profit of equity-accounted investees, net of tax  (595)      -                    -         -           -               (595)
 Adjusted EBITDA                                            15,980     19,017               108       (3,924)     -               31,181
 Exceptional - restructuring/acquisition related items      -          (220)                18        218         -               16
 EBITDA                                                     15,980     18,797               126       (3,706)     -               31,197
 Depreciation and impairment                                (5,322)    (2,236)              (12,251)  (88)        -               (19,897)
 Amortisation and impairment                                (1,695)    (15,000)             (2,463)   (3)         -               (19,161)
 Operating profit/(loss)                                    8,963      1,561                (14,588)  (3,797)     -               (7,861)
 Finance cost                                                                                                                     (20,057)
 Finance income                                                                                                                   4,741
 Loss before tax                                                                                                                  (23,177)

 

 Year ended 30 September 2021                             Genetics  Advanced Nutrition  Health    Corporate  Inter-segment sales  Total

                                                           £000      £000                £000      £000       £000                 £000
 Revenue                                                  46,797    70,530              7,832     4,820      (4,917)              125,062
 Cost of sales                                            (20,866)  (34,562)            (4,118)   2          67                   (59,477)
 Gross profit/(loss)                                      25,931    35,968              3,714     4,822      (4,850)              65,585
 Research and development costs                           (4,865)   (1,948)             (197)     -          -                    (7,010)
 Other operating costs                                    (8,933)   (19,918)            (6,202)   (8,018)    4,850                (38,221)
 Share of loss of equity-accounted investees, net of tax  (605)     (300)               -         -          -                    (905)
 Adjusted EBITDA                                          11,528    13,802              (2,685)   (3,196)    -                    19,449
 Exceptional - restructuring/acquisition-related items    850       (356)               (515)     (163)      -                    (184)
 EBITDA                                                   12,378    13,446              (3,200)   (3,359)    -                    19,265
 Depreciation and impairment                              (4,166)   (2,154)             (1,871)   (168)      -                    (8,359)
 Amortisation and impairment                              (1,338)   (13,896)            (1,047)   (2)        -                    (16,283)
 Operating profit/(loss)                                  6,874     (2,604)             (6,118)   (3,529)    -                    (5,377)
 Finance cost                                                                                                                     (7,987)
 Finance income                                                                                                                   4,185
 Loss before tax                                                                                                                  (9,179)

 

Non-current assets by location of assets

                 2022     2021

                 £000     £000
 Belgium         173,135  156,998
 Norway          83,752   86,545
 UK              42,373   44,629
 Iceland         39,448   35,062
 Rest of Europe  953      1,062
 Rest of world   38,543   33,668
                 378,204  357,964

 

3.     Net finance costs

 

                                                                       2022      2021

                                                                       £000      £000
 Interest received on bank deposits                                    319       88
 Foreign exchange gains on financing activities                        4,422     786
 Foreign exchange gains on operating activities                        -         1,957
 Cash flow hedges - reclassified from OCI                              -         (709)
 Cash flow hedges - ineffective portion of changes in fair value       -         2,063
 Finance income                                                        4,741     4,185
 Finance leases (interest portion)                                     (1,744)   (1,076)
 Cash flow hedges - reclassified from OCI                              (2,546)   -
 Cash flow hedges - ineffective portion of changes in fair value       (4,475)   -
 Foreign exchange losses on operating activities                       (1,620)   -
 Interest expense on financial liabilities measured at amortised cost  (9,672)   (6,911)
 Finance costs                                                         (20,057)  (7,987)
 Net finance costs recognised in profit or loss                        (15,316)  (3,802)

 

 

4.     Exceptional items - restructuring/acquisition-related items

Items that are material because of their nature, non-recurring or whose
significance is sufficient to warrant separate disclosure and identification
within the consolidated financial statements are referred to as exceptional
items. The separate reporting of exceptional items helps to provide an
understanding of the Group's underlying performance.

 

                                  2022     2021

                                  £000     £000
 Acquisition-related items        -        (850)
 Exceptional restructuring costs  1,229    480
 Cost in relation to disposals    (1,245)  554
 Total exceptional items          (16)     184

 

Acquisition-related items are costs incurred in investigating and acquiring
new businesses. In 2021 contingent consideration of

£850,000 was released in relation to the purchase of Benchmark Genetics (USA)
Inc.

 

Exceptional costs include: £843,000 (2021: £nil) of legal and professional
costs in relation to preparing for listing the Group on the Oslo stock
exchange, and £276,000 (2021: £480,000) relating to restructuring costs.

 

Costs in relation to disposals includes a credit of £1,203,000 (2021: £nil)
in relation to additional contingent consideration received and receivable
from disposals in previous years (£294,000 relating to the disposal of
Aquaculture UK on 7 February 2020, and £909,000 relating to the disposal of
Improve International Limited and its subsidiaries on 23 June 2020) together
with legal fees, lease costs and disposal items (net of proceeds received)
totalling £42,000 relating to additional costs and disposals proceeds
relating to disposals that occurred in 2020.

 

5.     Loss per share

Basic loss per share is calculated by dividing the profit or loss attributable
to ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.

 

                                                            2022      2021
 Loss attributable to equity holders of the parent (£000)   (32,087)  (12,891)
 Weighted average number of shares in issue (thousands)     698,233   669,459
 Basic loss per share (pence)                               (4.60)    (1.93)

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value based on the monetary value of the
subscription rights attached to outstanding share options and warrants.

 

A total of 6,240,304 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (2021:
4,615,712) as they are anti-dilutive and reduce the loss per share. However,
these potential ordinary shares could dilute earnings per share in the future.

 

6.     Property, plant and equipment

 

Group

 

                                                                     Freehold Land and Buildings  Assets in the course of construction  Long-Term Leasehold Property  Plant and Machinery  Office Equipment and Fixtures  Total

                                                                     £000                         £000                                  Improvements                  £000                 £000                           £000

                                                                                                                                        £000
 Cost
 Balance at 1 October 2020                                           57,856                       1,213                                 5,967                         25,149               2,596                          92,781
 Additions                                                           4,461                        4,118                                 841                           7,608                955                            17,983
 Reclassification                                                    (2,075)                      (371)                                 38                            2,414                (6)                            -
 Increase/(decrease) through transfers from assets in the course of
 construction

                                                                     3,080                        (3,080)                               -                             -                    -                              -
 Exchange differences                                                (5)                          (73)                                  (22)                          (1,107)              (206)                          (1,413)
 Disposals                                                           (290)                        -                                     (403)                         (1,171)              (588)                          (2,452)
 Balance at 30 September 2021                                        63,027                       1,807                                 6,421                         32,893               2,751                          106,899
 Balance at 1 October 2021                                           63,027                       1,807                                 6,421                         32,893               2,751                          106,899
 Additions                                                           4,025                        1,616                                 283                           4,546                338                            10,808
 Re-classification to inventory                                      -                            -                                     -                             (1,514)              -                              (1,514)
 Increase/(decrease) through transfers from assets in the course of  251                          (1,275)                               -                             995                  29                             -
 construction
 Exchange differences                                                1,924                        116                                   432                           2,377                146                            4,995
 Disposals                                                           (224)                        -                                     -                             (131)                (126)                          (481)
 Balance at 30 September 2022                                        69,003                       2,264                                 7,136                         39,166               3,138                          120,707
 Accumulated depreciation
 Balance at 1 October 2020                                           6,481                        -                                     4,984                         14,669               1,046                          27,180
 Depreciation charge for the year                                    2,120                        -                                     192                           2,379                486                            5,177
 Reversal of impairment in the year                                  -                            -                                     -                             (160)                -                              (160)
 Exchange differences                                                (541)                        -                                     (63)                          (986)                (196)                          (1,786)
 Disposals                                                           (231)                        -                                     (390)                         (1,096)              (575)                          (2,292)
 Balance at 30 September 2021                                        7,829                        -                                     4,723                         14,806               761                            28,119
 Balance at 1 October 2022                                           7,829                        -                                     4,723                         14,806               761                            28,119
 Depreciation charge for the year                                    2,387                        -                                     197                           5,411                607                            8,602
 Exchange differences                                                792                          -                                     256                           1,200                141                            2,389
 Disposals                                                           (84)                         -                                     -                             (102)                (117)                          (303)
 Balance at 30 September 2022                                        10,924                       -                                     5,176                         21,315               1,392                          38,807
 Net book value
 At 30 September 2022                                                58,079                       2,264                                 1,960                         17,851               1,746                          81,900
 At 30 September 2021                                                55,198                       1,807                                 1,698                         18,087               1,990                          78,780
 At 1 October 2020                                                   51,375                       1,213                                 983                           10,480               1,550                          65.601

 

 

7.     Leases

 

Group

 Right-of-use assets            2022    2021

                                £000    £000
 Leasehold property             9,389   9,859
 Plant and machinery            17,582  15,541
 Office equipment and fixtures  63      131
                                27,034  25,531

 Lease liabilities              2022    2021

                                £000    £000
 Current                        11,522  9,042
 Non-current                    14,765  14,945
                                26,287  23,987

 

 Depreciation charge of right-of-use assets           2021    2020

                                                      £000    £000
 Leasehold property                                   1,383   1,450
 Plant and machinery                                  9,176   1,718
 Office equipment and fixtures                        72      74
                                                      10,631  3,242

 Additional information                               2021    2020

                                                      £000    £000
 Additions to right-of-use assets                     497     18,721
 Modifications to right-of-use assets                 10,884  -
 Impairment of leasehold property right-of-use asset  664     100
 Interest expense                                     1,744   1,076
 Expense relating to short-term leases                152     371
 Expense relating to leases of low-value leases       151     58
 Total cash outflow for leases                        10,533  6,107

 

Benchmark Animal Health Limited modified the existing leases for two PSV
vessels, the FS Aquarius and the FS Pegasus to extend the lease term only.
These two assets constitute £15,741,399 of the net book value and
£15,358,543 of the lease liability at the year end.

 

8.     Intangible assets

 

Group

 

                                          Websites  Goodwill  Patents and Trademarks  Intellectual Property  Customer Lists  Contracts  Licences  Genetics  Development costs  Total

                                          £000      £000      £000                    £000                   £000            £000       £000      £000      £000               £000
 Cost or valuation
 Balance at 1 October 2020                201       144,346   270                     138,718                5,497           6,561      35,559    22,182    23,057             376,391
 Additions -                              115       -         68                      -                      -               -          42        -         -                  225

 externally acquired
 Additions - internally developed         -         -         -                       -                      -               -          -         -         4,813              4,813
 Exchange differences                     3         (4,291)   -                       (5,517)                (226)           41         (1,122)   454       (291)              (10,949)
 Balance at                               319       140,055   338                     133,201                5,271           6,602      34,479    22,636    27,579             370,480

 30 September 2021
 Balance at 1 October 2021                319       140,055   338                     133,201                5,271           6,602      34,479    22,636    27,579             370,480
 Additions - externally acquired          94        -         111                     -                      -               -          -         -         -                  205
 Additions - internally developed         -         -         -                       -                      -               -          -         -         1,708              1,708
 Exchange differences                     34        24,619    3                       27,206                 1,107           (27)       5,841     599       1,935              61,317
 Balance at                               447       164,674   452                     160,407                6,378           6,575      40,320    23,235    31,222             433,710

 30 September 2022
 Accumulated amortisation and impairment
 Balance at 1 October 2020                26        43,101    81                      63,163                 1,005           6,114      11,376    3,431     1,091              129,388
 Amortisation charge for the period       41        -         53                      12,707                 199             66         1,909     622       299                15,896
 Impairment                               -         -         -                       -                      -               -          -         -         387                387
 Exchange differences                     -         (1,743)   (1)                     (2,329)                (38)            30         (208)     58        -                  (4,231)
 Balance at 30 September 2021             67        41,358    133                     73,541                 1,166           6,210      13,077    4,111     1,777              141,440
 Balance at 1 October 2021                67        41,358    133                     73,541                 1,166           6,210      13,077    4,111     1,777              141,440
 Amortisation charge for the period       67        -         70                      13,574                 215             102        2027      636       2,165              18,856
 Impairment                               -         -         -                       305                    -               -          -         -         -                  305
 Exchange differences                     9         8,592     3                       16,966                 275             (19)       1,839     139       41                 27,845
 Balance at 30 September 2022             143       49,950    206                     104,386                1,656           6,293      16,943    4,886     3,983              188,446
 Net book value
 At 30 September 2022                     304       114,724   246                     56,021                 4,722           282        23,377    18,349    27,239             245,264
 At 30 September 2021                     252       98,697    205                     59,660                 4,105           392        21,402    18,525    25,802             229,040
 At 1 October 2020                        175       101,245   189                     75,555                 4,492           447        24,183    18,751    21,966             247,003

 

The table below provides further detail of intangibles and their remaining
amortisation period.

 

 Description                                                                  Category               Net book value  Net book value  Remaining

                                                                                                     2022            2021            life

                                                                                                                                     2022
 Acquisition of INVE in 2015
 Goodwill                                                                     Goodwill               87,585          72,385          -
 Harvesting rights                                                            Licences               22,449          19,599          13
 Product technology                                                           Intellectual property  446             1,843           0
 Product rights                                                               Intellectual property  39,390          42,571          3
 Brand names                                                                  Intellectual property  12,976          11,533          13
 In-process R&D                                                               Intellectual property  847             915             3
 Customer relationships                                                       Customer lists         4,723           4,105           19
 Total relating to acquisition of INVE                                                               168,416         152,951
 Acquisition of Salmobreed AS (Now part of Benchmark Genetics Norway AS) in
 2014
 Goodwill                                                                     Goodwill               6,523           6,703           -
 Genetic material and breeding nuclei                                         Genetics               9,911           10,500          32
 Total relating to acquisition of Salmobreed AS                                                      16,434          17,203
 Acquisition of Stofnfiskur (now Benchmark Genetics Iceland) in 2014
 Goodwill                                                                     Goodwill               12,467          11,394          -
 Genetic material and breeding nuclei                                         Genetics               8,147           7,677           32
 Total relating to acquisition of Stofnfiskur                                                        20,614          19,071
 Acquisition of Akvaforsk Genetics Center AS (Now part of Benchmark Genetics
 Norway AS) in 2015
 Goodwill                                                                     Goodwill               7,348           7,552           -
 Licences                                                                     Licences               292             662             1
 Contracts                                                                    Contracts              282             392             3
 Total relating to acquisition of Akvaforsk Genetics Center AS                                       7,922           8,606
 Capitalised development costs
 Ectosan(®)Vet/CleanTreat(®)                                                  Development costs      15,840          17,621          9
 Live food alternative diets                                                  Development costs      4,115           3,318            Not yet ready for use
 SPR shrimp                                                                   Development costs      6,686           4,863            Not yet ready for use
 Total capitalised development costs                                                                 26,641          25,802
 Other purchased material intangible assets                                   Intellectual property  1,497           1,586           17
 Total relating to other purchased intangible assets                                                 1,497           1,586
 Other individually immaterial goodwill and intangible assets                                        3,740           3,821
 Total net book value at 30 September                                                                245,264         229,040

 

9.     Impairment testing of goodwill and other intangible assets

 

The Group tests goodwill and other intangibles not yet ready for use annually
for impairment, or more frequently if there are indications that goodwill or
the other intangible assets might be impaired. Goodwill acquired in a business
combination is allocated, at acquisition, to the cash generating units (CGUs)
that are expected to benefit from the business combination. The only
intangible assets not yet ready for use are generally the capitalised
development costs on internally developed products. Following the commercial
launch of the SPR Shrimp product in Genetics, amortisation of these
development costs commenced during the year. The development costs included in
the table below represents only those that are not yet ready for use.

 

Due to the interdependence of the operations within each of the business areas
and the way in which they are managed, management have determined the CGUs are
the business areas themselves - Health, Genetics and Advanced Nutrition. These
are the smallest groups of assets that independently generate cashflows and
whose cashflows are largely independent of those generated by other assets.
Goodwill and capitalised development costs arise across the Group, and are
allocated specifically against the CGUs as follows:

 

                                                              Genetics  Advanced Nutrition  Health  Total

                                                              2022      2022                2022    2022

                                                              £000      £000                £000    £000
 Benchmark Genetics Norway AS                                 6,523     -                   -       6,523
 Benchmark Genetics Iceland HF (Previously Stofnfiskur HF)    12,467    -                   -       12,467
 Akvaforsk Genetic Center*                                    8,150     -                   -       8,150
 INVE Aquaculture Group                                       -         87,585              -       87,585
 Goodwill                                                     27,140    87,585              -       114,725
 Other intangibles not yet ready for use - development costs  -         4,115               -       4,115

 

*  Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).

 

                                                              Genetics  Advanced Nutrition  Health  Total

                                                              2021      2021                2021    2021

                                                              £000      £000                £000    £000
 Benchmark Genetics Norway AS                                 6,702     -                   -       6,702
 Benchmark Genetics Iceland HF (Previously Stofnfiskur HF)    11,394    -                   -       11,394
 Akvaforsk Genetic Center*                                    8,216     -                   -       8,216
 INVE Aquaculture Group                                       -         72,385              -       72,385
 Goodwill                                                     26,312    72,385              -       98,697
 Other intangibles not yet ready for use - development costs  4,863     3,318               -       8,181

 

*  Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).

 

The recoverable amounts of the above CGUs have been determined from
value-in-use calculations. These calculations used Board approved cash flow
projections from five-year business plans based on actual operating results
and current forecasts. These forecasts were then extrapolated into perpetuity
taking account of specific terminal growth rates for future cash flows, using
individual business operating margins based on past experience and future
expectations in light of anticipated economic and market conditions. The
pre-tax cash flows that these projections produced were discounted at pre-tax
discount rates based on the Group's beta adjusted cost of capital, further
adjusted to reflect management's assessment of specific risks related to the
markets and other factors pertaining to each CGU. Forecasts also include any
costs in relation to the Group's climate change strategy and climate change
factors have been considered when setting the long-term growth rates.

 

The values assigned to the key assumptions represent management's assessment
of future trends in the relevant industries and have been based on historical
data from both external and internal sources.

 

Specific assumptions used are as follows:

 

Genetics

Amortisation of the development costs relating to the business area's new SPR
Shrimp product commenced in the period.

 

The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 14.7% (2021: 10.9%). CAGR of revenue of 15% (2021:
14%) is implied by the five-year plan and a long-term growth rate of 2.5%
(2021: 2.5%) has been used to extrapolate the terminal year cashflow into
perpetuity.

 

Having conducted a sensitivity analysis of key assumptions, no reasonably
possible changes that would result in the elimination

of all headroom were identified.

 

Advanced Nutrition

The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 15.6% (2021: 10.3%). CAGR of revenue of 10% (2021:
6%) is implied by the five-year plan and a long-term growth rate of 3.5%
(2021: 3.5%) has been used to extrapolate the terminal year cashflow into
perpetuity. Market analysis reports predict long-term growth rates of c5.0%,
and the health benefits of shrimp are still very much in evidence. Management
have used a long-term growth rate of 3.5% to represent both a prudent and
consistent approach for the CGU.

 

The value in use assessment is sensitive to changes in the key assumptions
used. All other assumptions being unchanged a decrease in the long-term growth
rate to 1.8% or an increase in the pre-tax discount rate to 16.8%, either of
which are considered to be reasonably possible, would reduce the headroom on
the Advanced Animal Nutrition CGU of £21.6m to nil.

 

Should the discount rate increase further than this, then an impairment of the
goodwill or development costs would be likely.

 

In the work done during the year in assessing the risks caused by climate
change, there is a risk associated with the water levels in the Great Salt
Lake which is a key source of artemia for the Group. The mitigating actions
noted in that review mean that this is not currently a trigger event causing
our forecasts to be sensitised for this risk. However, should the water levels
fall to a level that could not sustain production of artemia, this might lead
to an impairment. Were this to occur, other mitigating actions available to
the Group including obtaining artemia from other globally available sources
and exploiting our Diets portfolio to reduce the use of artemia in our feed
programmes would be explored. As a result, management believe that no
impairment to the carrying value of the intangible assets is required.

 

Health

The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 16.4% (2021: 12.6%). An assumed CAGR of revenue of
27% (2021: 70%) in the five-year plan reflects the importance of the
successful commercial ramp- up of the business area's new sea lice treatment
in the forecast period. A long-term growth rate of 0.0% (2021: 0.0%) has been
used to extrapolate the terminal year cashflow into perpetuity. The prudent
assumption in the long-term growth rate is intended to reflect that the
business area's new sea lice treatment is the principal source of cash
generation, and only benefits from patent protection against generic
competitors for a finite period of time.

 

The valuation of the Health cash generating unit indicates sufficient headroom
such that a reasonably possible change to key assumptions is unlikely to
result in an impairment in related development costs.

 

While the valuation of the Health cash-generating unit indicates sufficient
headroom such that any reasonably possible change to key assumptions is
unlikely to result in an impairment in related development costs,
commercialisation is at an early stage and in the unlikely event that this is
not successful, impairment could result.

 

10.  Biological assets

Book value of biological assets recognised at fair value

                                       2022    2021

 Group                                 £000    £000
 Salmon eggs                           14,037  9,830
 Salmon broodstock                     30,501  26,700
 Salmon milt                           606     365
 Lumpfish fingerlings                  1,090   1,104
 Shrimp                                424     366
 Total biological assets 30 September  46,658  38,365
 Analysed as
 Current                               25,780  17,121
 Non-current                           20,878  21,244
 Total biological assets 30 September  46,658  38,365

 

Change in book value of biological assets

                                                         2021      2020

                                                         £000      £000
 Biological assets 1 October                             38,365    32,469
 Increase from production                                48,067    36,872
 Reduction due to sales                                  (43,535)  (34,768)
 Other movements in biological assets                    4,532     2,104
 Foreign exchange movement before fair value adjustment  1,704     311
 Change in fair value through income statement           1,595     3,323
 Foreign exchange impact on fair value adjustment        462       158
 Biological assets 30 September                          46,658    38,365

 

Assumptions used for determining fair value of biological assets

IAS 41 requires that biological assets are accounted for at the estimated fair
value net of selling and harvesting costs. Fair value is measured in
accordance with IFRS 13 and is categorised into levels in the fair value
hierarchy.

 

The fair value inputs for salmon eggs are categorised as level 2. The
calculation of the fair value of the salmon eggs is based upon the current
seasonally adjusted selling prices for salmon eggs less transport and
incubation costs and taking account of the market capacity. The valuation also
takes account of the mortality rates of the eggs and expected life as sourced
from internally generated data.

 

The fair value inputs for salmon broodstock are categorised as level 3. The
broodstock contain generations of genetic improvements and cannot be valued
purely on the market weight of salmon. The Group does not sell its broodstock
commercially so there is no observable input in this respect. Therefore, the
calculation of the estimated fair value of salmon broodstock is primarily
based upon its main harvest output being salmon eggs, which are priced upon
the current seasonally adjusted selling prices for the Group's salmon eggs.
These prices are reduced for harvesting costs, freight costs, incubation costs
and market capacity to arrive at the net value of broodstock. The valuation
also reflects the internally generated data to arrive at the biomass. This
includes the weight of the broodstock, the yield that each kilogram of fish
will produce and mortality rates. The fish take four years to reach maturity,
and the age and biomass of the fish is taken into account in the fair value.
Finally, the valuation takes account of future expected sales volumes.

 

Change in book value of salmon broodstock

                                                         2022      2021

                                                         £000      £000
 Biological assets 1 October                             26,700    21,051
 Increase from production                                28,720    22,428
 Transfer to salmon eggs following harvesting            (26,509)  (19,602)
 Foreign exchange movement before fair value adjustment  1,326     169
 Change in fair value through income statement           (31)      2,530
 Foreign exchange impact on fair value adjustment        295       124
 Biological assets 30 September                          30,501    26,700

 

Significant unobservable inputs used in the valuation of salmon broodstock

                                                2022     2021
 Number of eggs valued in broodstock (m units)  222      192
 Average selling price per egg (GBP)            0.135    0.128
 Future costs per egg (GBP)                     (0.021)  (0.015)

 

The fair value inputs for lumpfish fingerlings and shrimp are categorised as
level 2. The calculation of the fair value of lumpfish fingerlings and shrimp
is valued on current selling prices less transport costs. Internally generated
data is used to incorporate mortality rates and the weight of the biomass.

 

The fair value inputs for salmon milt are categorised as level 3. Where we
have identified individual salmon carrying particular traits or disease
resistance, semen (milt) can be extracted and deep-frozen using
cryopreservation techniques (the process of freezing biological material at
extreme temperatures in liquid nitrogen). The calculation of the fair value of
milt is based on production and freezing costs and, where appropriate, an
uplift to recognise the additional selling price that can be achieved from
eggs fertilised by premium quality milt.

 

There is a presumption that fair value can be measured reliably for a
biological asset. However, we sometimes face a situation where alternative
estimates of fair value are determined to be clearly unreliable (for example,
where we establish a new broodstock farm in a new territory). In such a case,
that biological asset shall be measured at its cost less any accumulated
impairment losses. In the year this applied to £1,969,000 of broodstock in
Chile. As at 30 September the gross carrying amount was £4,704,000 (2021:
£4,674,000) and the accumulated impairment losses were £2,735,000 (2021:
£2,507,000).

 

The valuation models by their nature are based upon uncertain assumptions on
sales prices, market capacity, weight, mortality rates, yields and assessment
of the discounts to reflect the stages of maturity. The Group has a degree of
expertise in these assumptions but these assumptions are subject to change.
Relatively small changes in assumptions would have a significant impact on the
valuation. A 1% increase/decrease in assumed selling price would
increase/decrease the fair value of biological assets by £445,000. A 10%
increase/decrease in the biomass of salmon broodstock and the quantity of
salmon eggs valued would increase/decrease the fair value of those biological
assets by £4,450,000.

 

The Group is exposed to financial risks arising from changes in the market
value of the salmon eggs, lumpfish fingerlings and shrimp broodstock that it
sells. The Group does not anticipate that prices will decline significantly in
the foreseeable future and, therefore, has not entered into derivative or
other contracts to manage the risk of a decline in the price of its products.
The Group reviews its outlook for salmon eggs, lumpfish fingerlings and shrimp
broodstock prices regularly in considering the need for active financial risk
management.

 

Risk management strategy related to aquaculture activity

The Group is exposed to the following risks relating to its aquaculture
activities. These risks and management's strategies to mitigate them are
described below:

 

Regulatory and environmental risks

The nature of certain of the Group's operating activities exposes us to
certain significant risks to the environment, such as incidents associated
with releases of chemicals or hazardous substances when conducting our
operations, which could result in liability, fines, risk to our product
permissions and reputational damage. There is a risk that natural disasters
could lead to damage to infrastructure, loss of resources, products or
containment of hazardous substances. Our business activities could be
disrupted if we do not respond, or are perceived not to respond, in an
appropriate manner to any major crisis or if we are not able to restore or
replace critical operational capacity.

 

In mitigation we have implemented standards and requirements which govern key
risk management activities such as inspection, maintenance, testing, business
continuity and crisis response.

 

Biological risks

The Group is exposed to the risk of disease within the Group's own operations
and disease in the market resulting in possible border closures. In
mitigation, the Group:

-      Operates the highest levels of biosecurity.

-      Holds genetic stock at multiple sites and increasingly sources
from its own land-based salmon breeding facilities.

-      Operates containment zones which mitigates the risk of border
closures affecting its ability to import or export.

-      Has placed increased focus on insuring its biological stock.

 

Outputs and quantities held

Total output of aquaculture activity in the year was:

                       2022          2021
 Salmon eggs           291.1m units  242.0m units
 Lumpfish fingerlings  2.0m units    2.4m units

 

Total quantities held at 30 September were:

                       2022          2021
 Salmon eggs           103.9m units  79.9m units
 Salmon broodstock     1,737 tonnes  1,577 tonnes
 Lumpfish fingerlings  0.7m units    2.6m units

 

 

11.  Trade and other receivables

 Group                                                                      2022     2021

                                                                            £000     £000
 Trade receivables                                                          31,218   24,526
 Less: provision for impairment of trade receivables                        (2,748)  (2,493)
 Trade receivables - net                                                    28,470   22,033
 Total financial assets other than cash and cash equivalents measured at    28,470   22,033
 amortised cost
 Other receivables - contingent consideration                               887      1,028
 Total financial assets other than cash and cash equivalents classified as  887      1,028
 measured at fair value through profit and loss
 Prepayments                                                                14,989   11,114
 Other receivables                                                          12,031   12,323
 Total trade and other receivables                                          56,377   46,498

 

Other receivables relate to the following items: VAT recoverable £4,386,000
(2021: £2,650,000), research and development expenditure tax credits and
similar items £154,000 (2021: £472,000), the right to receive an agreed
proportion of a key supplier's harvest* £5,249,000 (2021: £7,302,200),
accrued income of £1,377,000 (2021: £348,000) and other amounts receivable
of £865,000 (2021: £1,551,000).

 

*A financial liability of £5,249,000 (2021: £7,302,200) is recognised
(within trade payables) for the amount invoiced and remaining outstanding at
the year-end in relation to the Group's contractual obligation to pay for a
specified share of the harvest of a supplier, regardless of delivery and
without recourse to the supplier. As at 30 September, as the Group has not
taken physical delivery of the harvested product and as the Group does not
control the harvested product, an 'other receivable' of £5,249,000 (2021:
£7,302,200) has been recorded in relation to the Group's right to receive the
product in the future.

 

The financial asset at fair value through profit and loss relates to
contingent consideration outstanding from the disposal of Improve
International Limited in FY20. This relates to deferred cash consideration
dependent on the delivery of certain future revenues in the financial year
ended 30 September 2022 and the fair value is derived from the likely
receivable amount based on current expectations of performance against the
targets.

 

The fair values of trade and other receivables measured at amortised cost are
not materially different to their carrying values. As at 30 September 2022
trade receivables of £5,943,000 (2021: £3,060,000) were past due but not
impaired. They relate to customers with no default history. The ageing
analysis of these receivables is as follows:

                         2022    2021

                         £000    £000
 Up to 3 months overdue  5,761   2,703
 3 to 6 months overdue   218     211
 6 to 12 months overdue  (36)    146
                         5,943   3,060

 

Movements on the Group provision for impairment of trade receivables are as
follows:

                                                           2022    2021

                                                           £000    £000
 At 1 October                                              2,493   3,216
 Provided during the year                                  281     54
 Unused provisions reversed                                (180)   (637)
 Receivables written off during the year as uncollectable  -       (22)
 Foreign exchange movements                                154     (118)
 At 30 September                                           2,748   2,493

 

The movement on the provision for impaired receivables has been included in
the operating costs line in the Consolidated Income Statement.

 

Other classes of financial assets included within trade and other receivables
do not contain impaired assets.

 

12. Trade and other payables

 Group                                                                           2022     2021

                                                                                 £000     £000
 Trade payables                                                                  22,149   20,690
 Other payables                                                                  1,127    1,978
 Accruals                                                                        17,636   15,812
 Other payables - tax and social security payments                               3,799    2,076
 Financial liabilities, excluding loans and borrowings, classified as financial  44,711   40,556
 liabilities measured at amortised cost
 Financial contracts - hedging instrument                                        7,991    972
 Financial liabilities, excluding loans and borrowings, classified as financial  7,991    972
 liabilities at fair value through profit or loss
 Financial contracts - hedging instrument                                        21       5,889
 Financial liabilities, excluding loans and borrowings, classified as financial  21       5,889
 liabilities at fair value through hedging reserve
 Deferred income                                                                 597      162
 Total trade and other payables                                                  53,320   47,579
 Less: non-current: contingent consideration in other payables and financial     (8,996)  (911)
 contracts
 Current portion                                                                 44,324   46,668

 

Of the financial contracts £8,387,000 (2021: £6.708,000) relates to a NOKUSD
floating to fixed cross-currency interest rate swap (CCS) and a NOK interest
rate swap (IRS), both of which were entered to fully match the timing and
tenor of the underlying new senior secured floating rate listed bond issue of
NOK 750m.

 

The floating-to-fixed NOK IRS (notional NOK 300m) is designated a cash flow
hedge where any changes in the fair value of the swap will be taken directly
to equity within the hedging reserve and recycled to profit or loss as the
bond impacts the profit or loss.

 

The NOKUSD CCS (notional NOK450m) has been separated into two synthetic swaps;
the first is a floating-to-fixed NOKGBP interest rate swap, being a cash flow
hedge of the foreign exchange and interest rate risk on NOK denominated debt.
The fair value of this synthetic swap is posted to the hedging reserve in
equity. The second synthetic swap is a fixed-to-fixed GBPUSD swap designated
as a net investment hedge in the USD net assets in the consolidated accounts
of Benchmark Holdings plc. The fair value of this leg is posted to the foreign
exchange translation reserve in equity.

 

13.  Loans and borrowings

Group

                             2022     2021

                             £000     £000
 Non-Current
 2025 750m NOK Loan notes    61,054   -
 2023 850m NOK Loan notes    -        75,478
 Bank borrowings             17,226   19,314
 Lease liabilities           14,765   14,945
                             93,045   109,737
 Current
 Bank borrowings             5,569    1,612
 Lease liabilities           11,522   9,042
                             17,091   10,654
 Total loans and borrowings  110,136  120,391

 

At 30 September 2022 the fair value of the unsecured floating rate listed
green bond of NOK 750m was not materially different to the nominal value and
has not been separately disclosed. At 30 September 2021 the fair value of 2023
850m NOK Loan notes was £73,981,000.

 

On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments, and is to be listed on the Oslo Stock Exchange. The proceeds were
used to repay the NOK 850m floating rate listed bond, originally raised in
June 2019.

 

A USD 15m Revolving Credit Facility ("RCF") has been provided by DNB Bank ASA
(50%) and HSBC UK Bank PLC (50%). At 30 September 2022 £4,000,000 was drawn
on this facility. The facility was undrawn at 30 September 2021.

 

Benchmark Genetics Salten AS (formerly SalmoBreed Salten AS) had the following
loans (which are ring-fenced debt without recourse to the remainder of the
Group) at 30 September 2022:

-       Term loan with a balance of NOK 165.6m (2021: NOK 180.0m)
provided by Nordea Bank Norge Abp. The loan is a five-year term loan ending
November 2023 at an interest rate of 2.5% above three-month NIBOR.

-       NOK 20.0m 12-month working capital facility provided by Nordea
Bank Norge Abp. This was undrawn at 30 September 2022 (2021: undrawn).

-       An additional NOK 17.5m overdraft facility was provided by
Nordea Bank Norge Abp during the year with maturity in December 2022. This
facility was undrawn at 30 September 2022.

-       Term loan with a balance of NOK 40.1m (2021: NOK 44.7m) provided
by Innovasjon Norge. The loan is a 12-and-a-half-year term loan maturing in
March 2031. The interest rate on this loan at 30 September 2022 was 4.95%. The
interest rate on this loan is variable.

-       NOK 21.75m loan provided by Salten Aqua ASA (the minority
shareholder). The loan attracts interest at 2.5% above three-month NIBOR and
is repayable on maturity of the Nordea term loan above.

 

Subsequent to the year end on 1 November 2022, the Nordea Bank term loan above
was refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms remain the same.

 

Furthermore on 21 November 2022, the Group refinanced the USD15m RCF with a
secured GBP20m RCF provided by DNB Bank ASA, maturing on 27 June 2025. The
margin on this facility is a minimum of 2.75% and a maximum of 3.25%,
dependent upon the leverage of the Group above the relevant risk free
reference or IBOR rates depending on which currency is drawn.

 

The lease liabilities are secured on the assets to which they relate.

 

The currency profile of the Group's loans and borrowings is as follows:

 

                  2022     2021

                  £000     £000
 Sterling         16,619   13,912
 Norwegian Krone  80,712   97,389
 Thai Baht        954      1,258
 Euro             272      351
 US Dollar        10,888   6,508
 Icelandic Krone  545      750
 Other            146      223
                  110,136  120,391

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR LKLLLLFLFFBQ

Recent news on Benchmark Holdings

See all news